Open AccessThe Human Adenoidal Mast Cell. Suceptibility to Different Secretagogues and Secretion Inhibitors
Author(s) -
W. Schmutzler,
K. Delmich,
Dieter Eichelberg,
Stefan Glück,
T. Greven,
H. Jürgensen,
K.P. Riesener,
G Risse,
P. Pult
Publication year - 1985
Publication title -
international archives of allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.696
H-Index - 100
eISSN - 1423-0097
pISSN - 1018-2438
DOI - 10.1159/000233778
Subject(s) - histamine , degranulation , mast cell , concanavalin a , secretion , population , stimulation , immunology , pharmacology , biology , chemistry , microbiology and biotechnology , endocrinology , in vitro , biochemistry , medicine , receptor , environmental health
Mast cells from adenoid tissues of man do not form a homogeneous population but differ in size and ultrastructure. They degranulate on stimulation with specific antigen, ionophore A 23187, Concanavalin A and, under certain conditions, antihuman IgE or acetylcholine. Compound 48/80, dextran, purified C3a or C5a are ineffective. Adenosine exerts either an enhancing or inhibiting effect on the stimulated histamine release, depending on the actual conditions of the mast cells. The study of a range of known mast cell degranulation inhibitors revealed important differences between human adenoidal mast cells and human basophils or animal mast cell systems. The efficacies of the drugs or drug combinations so far tested correspond well with the established therapeutic effects in man.